Dermata Therapeutics, Inc. (DRMA) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US2498455045
Dermata Therapeutics, Inc. financials
| Fiscal year | 2025 |
|---|---|
| Operating income | -7.77 m USD |
| EBIT | -7.77 m USD |
| Net income | -7.56 m USD |
| Diluted EPS – continuing operations | -8.16 USD |
Full history since 2019, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Dermata Therapeutics, Inc.
Dermata Therapeutics, Inc. engages in the development and distribution of over-the-counter pharmaceutical dermatology-focused products in the United States. The company develops direct-to-consumer skincare products, including foundation treatment products for skin renewal and clearing treatment products for the treatment of acne under the Tome brand. Dermata Therapeutics, Inc. was incorporated in 2014 and is headquartered in San Diego, California.
More stocks
- Healthcare Triangle, Inc. (HCTI)
- Fathom Holdings Inc. (FTHM)
- PATRIOT GOLD CORP (PGOL)
- Reliance Global Group, Inc. (EZRA)
- Singularity Future Technology Ltd. (SGLY)
- WEED, INC. (BUDZ)
- BestGofer Inc. (BGFR)
- MKDWELL Tech Inc. Ordinary Share (MKDW)
- CURIS INC (CRIS)
- Jet.AI Inc. (JTAI)
- Ernexa Therapeutics Inc. (ERNA)
- Arrive AI Inc. (ARAI)
Not investment advice. All data without warranty, price as of 13.11.2026. Details in the risk notice.